Role Of ProstaScint And Radionuclide Bone Scan In Prostate Cancer Diagnosis

Prostate Cancer that has metastasized to the remote locations mostly reaches the bones, but would continue to be known as prostate and not bone cancer. A Radionuclide bone scan comes into the picture to assist in showing if the cancer has inflicted the bones.

For performing a radionuclide bone scan a miniscule quantity of radioactive matter is administered as an intravenous shot after which the material would settle in the bone tissue that has faced damage all through the skeletal system in the span of a few hours.

The person is then requested to lay flat on a table for nearly thirty minutes during which time a specialised camera identifies the radioactive substance and produces an image of the skeletal structure.

Regions where the bone tissue have been damaged due to the cancer presence are visible as hot spots on the skeletal structure as they are drawn to radioactivity and thus are indicative of the existence of metastatic cancer. However, even in case a person is arthritic or is having other kind of bone ailments would also exhibit analogous hot spots in his/her skeleton during the scan. To exclude the presence of other non-cancer related conditions, the doctor would employ other methods of imaging like basic X-rays, CAT or MRI scanning for getting a clearer view of the regions that are lighting up, or the doctor might also draw biopsy samples from the bone.

The shot is slightly discomforting component of the scanning method. However, the radioactive matter is excreted out of the system in a span of the subsequent couple of days. As infinitesimal quantity of radioactive matter is employed hence it holds negligible risk to the concerned person.

ProstaScint Scan

Analogous to the radionuclide bone scan, the ProstaScint scan employs a shot of less amounts of radioactivity for detecting cancer metastasis that has grown past the prostate. Although the duo tests search for regions of accumulation of radioactive matter, however have diverse means of carrying it out.

The radioactive matter used in ProstaScint is drawn to the prostate cells and is joined to the monoclonal antibody – a form of synthetic protein which detects and affixes to a certain material in this scenario to the PSMA or prostate-specific membrane antigen that is present in elevated amounts in healthy and malignant prostate cells.

The benefit of undergoing this test is that it could detect prostate cancer cells present in the non-bony organs of the body. As the antibody merely adheres to the prostate cancer cells hence there is no likelihood of anomalous outcomes.

This scan is suggested for those males that have been lately detected with prostate cancer. However, it could be beneficial subsequent to treatment in case there is a surge in blood PSA levels and other testing methods are unable to detect the precise site of the cancer.

Popularity: 13% [?]